IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 04/05/2017 - Events

    Mutation discovered that, linked with drug, predisposes osteoporosis patients to femur fracture

    Researchers at the Hospital del Mar Medical Research Institute (IMIM) and the University of Barcelona have uncovered a mutation that makes bone vulnerable to bisphosphonates, drugs used to combat osteoporosis. Instead of strengthening bone and preventing fractures, these medicines induce a critical problem that makes the femur more prone to breaks. This discovery, enormously significant clinically, was published today in the New England Journal of Medicine, the most important biomedical journal in terms of potential impact. Osteoporosis causes fractures that affect up to 40% of people over the age of 50. Bisphosphonates are efficient and cheap, making them the first line of treatment for this condition. Nevertheless, they have been associated with atypical fracturing of the femur. "Despite the rarity of this complication and the fact that many more fractures are prevented than induced, fear of this complication has led to the prescription of these drugs being criticised, especially for long-term treatment", explains study leader Dr. Adolf Díez, emeritus head of internal medicine at Hospital del Mar and a researcher in the musculoskeletal research group at the IMIM. 

    Més informació "Mutation discovered that, linked with drug, predisposes osteoporosis patients to femur fracture"

  • 25/05/2016 - Events

    New evidence on molecular mechanisms involved in psoriasis outset

    Two translational research studies by the University of Barcelona have described new immunologic mechanisms in psoriasis, a chronic cutaneous inflammatory disease which affects around the 2% of the population. The studies, published in the high impact scientific magazines Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology , have analysed the molecular processes involved in the IL-17 cytokine –a protein family of the immune system- with samples of patients with psoriasis. These results are important to understand the origins of psoriasis and develop more specific pharmaceutical treatments, since the IL-17 blocking is a new therapeutic strategy which is very effective when controlling this illness. The studies have been led by Lluís Francesc Santamaria, Director of the group of Translationary Immunology of the University of Barcelona based at the Barcelona Science Park, together with researchers of the Hospital del Mar and the Municipal Institute for Medical Research, among others.

    Més informació "New evidence on molecular mechanisms involved in psoriasis outset"

  • 20/12/2011 - Events

    Bidding farewell to the participants of the PREDIMED study

    Last 14th December an event was held at the PRBB Auditorium; it was organized by the IMIM Group on Cardiovascular Risk and Nutrition to say goodbye to and thank the participants in the PREDIMED study, their involvement, availability and enthusiasm during the four years over which the project has developed (2003-2011).

    Més informació "Bidding farewell to the participants of the PREDIMED study"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact